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1. Introduction 
Pituitary adenomas (PAs) are common intracranial 
neoplasms arising from adenohypophysial cells. Their 
overall estimated prevalence is 16.7% (14.4% in autopsy 
studies and 22.5% in radiologic studies). Although they 
are benign tumors, they can lead to increased mortality 
because of hormone overproduction and compression or 
invasion of surrounding structures. In addition to genetic 
events, epigenetic changes, hormonal stimulation, growth 
factors and environmental agents, abnormal microRNA 
(miRNA) expression have also been reported to initiate 
and promote pituitary tumorigenesis. miRNAs are small 
[approximately 19-25 nucleotides] non-coding RNA 
molecules involved in the post-transcriptional regulation 
of gene expression. They have been implicated in many 
cellular processes, including cell proliferation, apoptosis, 
cell adhesion and metabolism either as activators – 
oncomiRs – or inhibitors – tumor suppressor miRNAs – 
of tumorigenesis. miRNAs have been described to be 
associated with pituitary tumor type, characteristics (size, 
invasion) and response to therapy as well as in the 
regulation of genes associated with the pathogenesis of 
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PAs. Pheochromocytomas and paragangliomas are 
benign or malignant tumours of the involuntary nervous 
system located in the adrenal gland or along the 
sympathetic or parasympathetic chain. Although both 
PAs and pheochromocytomas/paragangliomas 
(pheo/PGL) are relatively rare diseases, they can 
sometimes occur in the same patient or in the same 
family.  
 
2. Objectives 
The overall aim of the study was to investigate the 
genetic backround of pituitary tumor formation. 
Study I: Patients with germline aryl hydrocarbon 
receptor-interacting protein (AIP) mutations or with a 
sporadic somatotroph adenoma showing low AIP protein 
expression have large, invasive and difficult to treat  
somatotroph adenomas suggesting that low AIP 
expression is important in determining the pathological 
characteristics of somatotropinomas. Our objective was 
to investigate the miRNA regulation of AIP protein in 
sporadic somatotropinomas. 
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Study II: PA and pheo/PGL can occur in the same 
patient or in the same family, and classically they are not 
part of any multiple endocrine tumor syndrome together. 
Our aim was to study the possible role of mutations in the 
genes known to cause pheo/PGL in PA formation.  
 
3. Methods 
3.1. Patients 
Study I: Thirty-four consecutive somatroph adenomas 
were included in the study. Exclusion criteria included 
preoperative somatostatin-analogue therapy, positive 
family history or features of genetic origin of the PA. 
Five autopsy normal human pituitaries were used as 
controls. 
Study II: we collected clinical data, genomic DNA, and 
tumor tissue, where available, from 39 patients (from 27 
kindreds) with pheo/PGL and PA in a sporadic (n=19) or 
familial (n=20) setting. Probands from 23 FIPA families 
served as controls.  
 
3.2. Genetic studies 
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Study I: the entire coding sequence of AIP, the 
conserved splice sites and 1200 base pairs of the 
promoter region were direct sequenced in 
somatotropinomas. The AIP mRNA expression, the 
selected miRNA expressions and the endogenous AIP 
mRNA expression after miR-34a overexpression and 
inhibition were analyzed by real-time qPCR in 
somatotropinomas, normal pituitaries or HEK293 and 
GH3 cell lines. 
Study II: sequence analysis of the AIP, multiple 
endocrine neoplasia type 1 gene (MEN1), cyclin-
dependent kinase inhibitor 1B gene (CDKN1B, coding 
region and upstream open reading frame) was performed 
using Sanger sequencing and multiplex ligation-
dependent probe amplification (MLPA). Genes 
implicated in pheo/PGL (MYC-associated factor X 
(MAX), ’rearranged during transfection’ tyrosine kinase 
receptor gene (RET), succinate dehydrogenase subunit A 
(SDHA), succinate dehydrogenase complex assembly 
factor 2 (SDHAF2), succinate dehydrogenase subunit B 
(SDHB), succinate dehydrogenase subunit C (SDHC), 
succinate dehydrogenase subunit D (SDHD), 
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transmembrane protein 127 (TMEM 127) and von 
Hippel–Lindau gene (VHL) were analyzed using a 
combination of next generation sequencing, Sanger 
sequencing and MLPA. In addition, fumarate hydratase 
(FH) was studied in a subset of patients. Loss of 
heterozygosity study on the SDHB locus of the PA and 
MEN1 locus of the pheochromocytoma was performed 
on the available tumor samples.  
 
3.3. Immunohistochemistry 
Study I: For semi-quantitative estimate of cytoplasmic 
AIP immunostaining, slides were scored for pattern 
[diffuse (score 2) or patchy (score 1)] and for intensity 
[strong (score 3), moderate (score 2) and weak (score 1)], 
and the final score was calculated by multiplying the two 
scores (pattern and intensity), resulting in low (0, 1 or 2) 
or high (3, 4, or 6) AIP expression.  
Study II: Immunostaining for GHRH and MEN1 was 
performed on relevant pheo samples, while SDHA, 
SDHB immunostaining was performed on available 
pituitary tumor samples. Some pituitary samples had 
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anti-mitochondrial and anti-endoplasmic reticulum lectin 
1 (ERLEC1) staining. 
 
3.4. Target site prediction 
To identify AIP mRNA-miRNA interaction we initially 
used algorithms described in the miRNAmap prediction 
program. The mRNA-miRNA interaction was evaluated 
by three different criteria: (i) target site predicted by at 
least two prediction programs, (ii) the target gene 
contains multiple target sites for the miRNA and (iii) the 
target sites are located in accessible regions of the RNA 
as determined by a pre-specified algorithm. We selected 
to evaluate by qPCR miRNAs that reach all three 
miRNAmap criteria or at least two miRNAmap criteria 
and a negative Pearson correlation coefficients for each 
miRNA and the target gene at least -0.30. Moreover, in 
order to confirm and to complete our search for miRNAs 
interacting with AIP and to determine the exact miRNA 
target binding sites in both human and rat AIP we utilized 
TargetScan version 6.2, MicroCosm, FindTar version 3, 
miRanda and PicTar. 
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3.5. Cell line studies 
Rat GH- and prolactin-secreting PA cell line GH3, the 
human embryonic kidney cell line HEK293 and the 
human primary pancreatic adenocarcinoma BXPC3 cell 
line were used in the studies. A pGL3-AIP-3’-UTR 
vector was generated to examine whether the effect on 
the luciferase activity (using Dual-Luciferase Reporter 
Assay System) of the studied miRNAs was specifically 
due to binding to the predicted binding sites in wild type 
(WT) or mutated (using QuikChangeXL-site-directed 
mutagenesis kit) AIP-3’-UTR fragment. Cell viability, 
colony formation and wound-healing assay were used to 
assess proliferative potential. 
 
3.6. Statistical analysis 
The statistical analysis was performed using SPSS 
version 16.0 for Windows (SPSS, Inc., Chicago, IL, 
USA) or StatsDirect software (Addison-Wesley-
Longman, Cambridge, UK). P values < 0.05 were 
considered statistically significant. 
 
4. Results 
9 
 
4.1. Study I 
4.1.1. AIP protein and mRNA correlation 
All tumors expressed AIP, with low expression levels 
(score 1-2) observed in 13 cases (42%). Interestingly, 
there was no difference in the AIP mRNA expression 
between tumors with low or high AIP protein levels. 
These data lead us to the hypothesis that post-
transcriptional regulation, such as that exerted by 
miRNAs, may be the cause of the low AIP protein 
expression. 
 
4.1.2. miRNA expression levels 
Based on in silico predictions, we selected 11 miRNAs 
for analysis by real-time qPCR: let-7a, let-7b, miR-202, 
miR-22, miR-34a, miR-34c, miR-449b, miR-510, miR-
612, miR-639 and miR-671. Two miRNAs showed 
higher expression in tumors with low AIP protein levels 
compared to tumors with high AIP protein levels: miR-
22 and miR-34a. 
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4.1.3. Correlation of AIP expression, miR-22 and 
miR-34a levels with tumor invasiveness and response 
to somatostatin analogues 
Eleven out of 13 (85%) somatotropinomas with low AIP 
protein expression were invasive while 6 out of 18 (33%) 
somatotropinomas with high AIP expression were 
invasive (P=0.006).  The miR-34a levels did not differ 
significantly in invasive and in non-invasive 
somatotropinomas. A total of 26 patients were initiated 
on long-acting somatostatin analogue (OCT-LAR) after 
surgery. In 10 patients (38%) acromegaly was considered 
controlled after OCT-LAR therapy. Only one out of nine 
patients (11%) whose tumors presented low AIP 
expression achieved disease control with medical 
treatment, while nine out of 17 patients (53%) harboring 
tumors with high AIP expression achieved disease 
control with OCT-LAR therapy (P=0.045). The miR-34a 
levels were lower in those patients controlled with OCT-
LAR therapy than in the uncontrolled patients. 
 
4.1.4. miR-34a effect on regulation of AIP expression 
in vitro 
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There are three different predicted target seed regions for 
miR-34a in the human AIP-3’UTR sequence and miR-22 
has one binding site, located 42-47 bp downstream of the 
stop codon of human AIP. To verify the in silico 
predicted interaction between miR-34a and miR-22 and 
AIP, we used a pGL3 vector containing the human wild 
type AIP-3’UTR downstream of the coding sequence of 
Firefly luciferase. Transfection of pre-miR-34a precursor 
and WT-AIP-3’UTR into GH3 cells resulted in a 31±4% 
reduction of luciferase activity compared with the control 
scrambled miR (P<0.0001). Transfection of pre-miR-22 
precursor and WT- AIP-3’UTR into GH3 cells resulted in 
no reduction of the luciferase activity. 
 
4.1.5. Confirmation of predicted miR-34a binding 
sites 
To investigate which predicted binding site of miR-34a is 
involved in the miR-34a effect we used deletion mutants 
targeting the three different bindig sites: MUT_A for the 
mutated binding site A (c.*6-30), MUT_B for site B and 
MUT_C for site C. MUT_A leads to a complete loss of 
miR-34a effect on luciferase activity, while MUT_B and 
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MUT_C did not change the inhibitory effect of miR-34a 
on the luciferase assay.  
 
4.1.6. Regulation of endogenous AIP expression by 
miR-34a in vitro 
To further characterize the interaction of miR-34a and 
AIP in vitro we measured mRNA and protein levels of 
endogenous AIP after miR-34a overexpression and 
inhibition in HEK293 and GH3 cells. Significant 
decrease in AIP protein level was observed 48h post-
transfection with miR-34a compared to scrambled miR 
control (HEK293 n=7, 17±3%, P=0.001, GH3 n=4, 
25±1%, P=0.0005), suggesting that high levels of miR-
34a can suppress endogenous AIP protein expression in 
vitro. Although miR-34a overexpression induced a 
significant decrease in endogenous AIP protein levels, no 
significant change was seen at the mRNA level in 
HEK293 and GH3 cells. 
 
4.1.7. The effect of miR-34a on cell proliferation and 
colony formation 
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To determine the biological effect of miR-34a 
overexpression, we investigated its effect on cell 
proliferation and colony formation in BXPC3 and GH3 
cells. Using a cell proliferation assay we observed a 
significant increase in the number of living cells in 
culture 24h and 48h post-transfection (13±3% P=0.007, 
9±5% P=0.02). In case of the wound-healing assay and 
colony formation assay the difference were not 
significant. 
 
4.2. Study II 
4.2.1. Genetic screening 
Germline alterations were identified in SDHA, SDHB, 
SDHC, SDHD, SDHAF2, VHL and MEN1 genes in 19 
patients with pheo/PGL and/or PAs. Twenty patients had 
no identifiable mutations in any of the genes tested.  
None of the patients in our cohort had AIP or CDKN1B 
mutations. We identified 11 kindreds (including 16 
patients) with germline SDHX variants.  Seven families 
had a pathogenic SDH mutation, while 4 had a variant of 
unknown significance. In the PAs, where suitable sample 
was available, we identified the loss of the wild-type 
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allele in the adenoma sample compared to the germline 
DNA. We identified two patients with germline MEN1 
mutation and pheochromocytoma, while all the other 
tested genes were normal. Both pheochromocytomas 
showed LOH in the MEN1 gene. 
 
4.2.2. Pathological features 
The PAs of patients with SDHX mutations were 
characterized by intracytoplasmic vacuoles. The 
histochemical stain periodic acid of Schiff 
(PAS)/diastase-resistant PAS (DPAS) did not reveal any 
glycogen accumulation. As SDHX mutations are known 
to alter mitochondrial function, immunostaining was 
performed for a mitochondrial membrane protein with 
the anti-113-1 antibody. Vacuoles did not appear to be 
rimmed by this protein suggesting that vacuolization is 
not secondary to dilatation of mitochondria. To 
understand if vacuoles were the result of swelling of the 
endoplasmic reticulum (ER), we immunostained our 
samples for the ER marker ERLEC1. None of the 
vacuoles was lined by this protein indicating that they 
were not releated to the ER. We used electron 
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microscopy to further study the nature of vacuoles. 
Interpretation of ultrastructural features of the tissue 
retrived from paraffin was limited by suboptimal 
preservation. The cytoplasm appeared to contain large 
empty vacuoles unrelated to mitochondria and no 
obvious membrane were identified to rim vacuoles. 
Menin staining of the pheochromocytoma samples of 
patients with MEN1 mutations showed either no menin 
positive cells or weakly positive staining nuclei. 
 
5. Conclusion 
5.1. Study I 
In this study we showed that low AIP protein levels in 
human sporadic somatotropinomas are associated with 
high miR-34a expression and that miR-34a can down-
regulate AIP protein levels in in vitro experiments. In 
addition, we showed that high miR-34a levels are 
associated with a lower chance of acromegaly control 
with SSA therapy and we confirmed our previous 
findings that low AIP protein expression is associated 
with a poor response to SSA. Our data demonstrates that 
the inhibition involves AIP translation repression without 
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reduction in AIP mRNA, as there was no difference in 
the AIP mRNA levels between tumors with low or high 
AIP protein levels. Our findings showed that miR-34a 
down-regulates AIP protein levels, while miR-22 had no 
inhibitory effect. Our data suggest that miR-34a reduce 
AIP expression via binding to c.*6-30 at the AIP-3’UTR. 
Endogenous AIP protein expression is inhibited by 
overexpression of miR-34a in vitro in GH3 and HEK293 
cells, leading to increased cell viability. 
In conclusion, we have demonstrated that miR-34a is 
overexpressed in sporadic somatotropinomas with low 
AIP protein levels in the absence of mutations in this 
gene and that this overexpression is inversely correlated 
to the response to SSA. Functional studies confirmed that 
miR-34a down-regulates AIP expression, suggesting the 
possible involvement of miR-34a in the pathogenesis of 
sporadic somatotropinomas. 
 
5.2. Study II 
Syndromic presentation of PA and pheo/PGL is rare and 
it is not part of the classical multiple endocrine tumor 
syndromes. Germline mutations were identified in the 
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studied PA or pheo/PGL causing genes in 11/27 kindreds 
with the combination of pheo/PGL and PAs. We show 
that pituitary adenomas occur in patients with SDHX 
mutations and their pathogensis is likely to depend on the 
SDHX mutation. We also confirm that MEN1 mutation 
can predispose to pheochromocytomas.  An endocrine 
rather than genetic causation can link 
pheochromocytomas secreting hypothalamic releasing 
hormones (GHRH or CRH) with pituitary changes 
mimicking the PAs and these cases may present a clinical 
differential diagnostic problem. In about half of our cases 
no germline abnormalities were seen, suggesting either 
the presence of other disease-causing genes or the 
coincidental occurrence of the pituitary and pheo/PGL 
tumors. We have identified a novel feature of the PAs of 
patients harboring SDHX variants. The adenoma tissues 
show extensive vacuolization of cytoplasm. The origin of 
vacuoles remains unclear. Inactivation of succinate 
dehydrogenase or VHL can lead to activation of the 
hypoxia inducible factor  (HIF) pathway and a 
pseudohypoxic state. Indeed, it has been shown increased 
HIF-1α in an SDHD mutated case linked to PA.  It is not 
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known whether the vacuoles seen in the SDH-related 
tumors are due to the pseudohypoxic state, but we did not 
observe this phenomenon in the VHL mutation-related 
PA. Immunostaining for a mitochondrial membrane 
protein or for an ER marker did not prove that the 
vacuoles arise from these organelles. 
In conclusion, mutations in the genes known to cause 
pheo/PGL can rarely be associated with  PAs, while 
mutation in a gene predisposing to PAs (MEN1) can be 
associated with pheo/PGL. Our findings suggest that 
genetic testing should be considered in all patients or 
families with the constellation of pheo/PGL and PA.  
 
6. Bibliography of the candidate's publications 
Related to the thesis:  
1. Dénes J, Korbonits M, Hubina E, Kovács GL, Kovács 
L, Görömbey Z, Czirják S, Góth. (2011) 
Familial isolated pituitary adenoma syndrome. Orv Hetil, 
152: 722-730. 
2. Boguszewski CL, Fighera TM, Bornschein A, 
Marques FM, Dénes J, Rattenbery E, Maher ER, Stals K, 
Ellard S, Korbonits M. (2012) Genetic studies in a 
19 
 
coexistence of acromegaly, pheochromocytoma, 
gastrointestinal stromal tumor (GIST) and thyroid 
follicular adenoma. Arq Bras Endocrinol Metabol, 56: 
507-512. IF: 0.682 
3. Rattenberry E, Vialard L, Yeung A, Bair H, McKay 
K, Jafri M, Canham N, Cole TR, Denes J, Hodgson 
SV, Irving R, Izatt L, Korbonits M,Kumar AV, Lalloo 
F, Morrison PJ, Woodward ER, Macdonald F, Wallis 
Y, Maher ER. (2013) A comprehensive next generation 
sequencing based genetic testing strategy to improve 
diagnosis of inherited pheochromocytoma and 
paraganglioma. J Clin Endocrinol Metab, 98: E1248-56. 
IF: 6.310 
4. Dénes J, Kasuki L, Trivellin G, Colli LM, Takiya CM, 
Stiles CE, Barry S, De Castro M, Gadelha M, Korbonits 
M. (2015) Regulation of aryl hydrocarbon receptor 
interacting protein (AIP) protein expression by miR-34a 
in sporadic somatotropinomas. PlosOne, 10: e0117107. 
IF: 3.534 
5. Dénes J, Swords F, Rattenberry E, Stals K, Owens M, 
Cranston T, Xekouki P, Moran L, Kumar A, Wassif C, 
Fersht N, Baldeweg SE, Morris D, Lightman S, Agha A, 
20 
 
Rees A, Grieve J, Powell M, Luiz Boguszewski C, Dutta 
P, Thakker RV, Srirangalingam U, Thompson CJ, Druce 
M, Higham C, Davis J, Eeles R, Stevenson M, O'Sullivan 
B, Taniere P, Skordilis K, Gabrovska P, Barlier A, Webb 
SM, Aulinas A, Drake WM, Bevan JS, Preda C, 
Dalantaeva N, Ribeiro-Oliveira A Jr, Tena Garcia I, 
Yordanova G, Iotova V, Evanson J, Grossman AB, 
Trouillas J, Ellard S, Stratakis CA, Maher ER, Roncaroli 
F, Korbonits M. (2015) Heterogeneous genetic 
background of the association of 
pheochromocytoma/paraganglioma and pituitary 
adenoma - results from a large patient cohort. J Clin 
Endocrinol Metab, 100: E531-541. IF: 6.310 
 
Not related to the thesis: 
1. Dénes J, Korbonits M, Hubina E, Góth M. (2010) The 
treatment of acromegaly. Orv Hetil, 151: 1384-1393. 
2. Dénes J, Hubina E, Góth M. (2011) Growth hormone 
replacement therapy in growth hormone deficient adults. 
Háziorvos Továbbképző Szemle (Journal of Postgraduate 
Course for General Practioner), 16: 389. 
21 
 
3. Kovács GL, Dénes J, Hubina E, Kovács L, Czirják S, 
Góth M. (2011)  The change of consensus on criteria for 
cure of acromegaly during the last decade. Orv Hetil, 
152: 703-708. 
4. Hubina E, Tóth Á, Kovács GL, Dénes J, Kovács L, 
Góth M. (2011) Growth hormone receptor antagonist int 
he treatment of acromegaly. Orv Hetil, 152: 709-714. 
5. Kovács GL, Szabolcs I, Görömbey Z, Kovács L, 
Hubina E, Dénes J, Kósa R, Góth M. (2011) The 
possible connection between Borrelia burgdorferi and 
Riedel thyreoiditis. Case report  and review of the 
literature. Magy Belorv Arch, 64: 300-306. 
6. Dinesen PT, Dal J, Gabrovska P, Gaustadnes M, 
Gravholt CH, Stals K, Denes J, Asa SL, Korbonits M, 
Jørgensen OL. (2015) An unusual case of an 
adrenocorticotropin-secreting macroadenoma with a 
germline variant in the aryl hydrocarbon receptor 
interacting protein (AIP) gene. Endocrinol Diabetes 
Metab Case Rep, 2015: 140105. 
 
